Rossi V, Hochkoeppler A, Govoni M, Di Stefano G
Cells. 2024; 13(18.
PMID: 39329717
PMC: 11430493.
DOI: 10.3390/cells13181533.
Vidimar V, Park M, Stubbs C, Ingram N, Qiang W, Zhang S
Mol Cancer Ther. 2022; 21(5):810-820.
PMID: 35247912
PMC: 9933180.
DOI: 10.1158/1535-7163.MCT-21-0550.
Lewis C, Karve A, Matiash K, Stone T, Li J, Wang J
Front Oncol. 2021; 11:691685.
PMID: 34395257
PMC: 8358774.
DOI: 10.3389/fonc.2021.691685.
Wu Y, Liu Z, Tang D, Liu H, Luo S, Stinchcombe T
Transl Res. 2021; 233:92-103.
PMID: 33400994
PMC: 8184605.
DOI: 10.1016/j.trsl.2020.12.009.
Hsieh C, Chou Y, Kuo M, Tsai H, Chang J, Wu C
Oncogene. 2017; 36(21):2946-2956.
PMID: 28092674
DOI: 10.1038/onc.2016.465.
Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells.
Ota I, Higashiyama S, Masui T, Yane K, Hosoi H, Matsuura N
Oncol Rep. 2013; 30(4):1593-600.
PMID: 23917679
PMC: 3810215.
DOI: 10.3892/or.2013.2659.
Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia.
Ray K, Moss M, Franklin J, Weaver C, Higginbotham J, Song Y
Oncogene. 2013; 33(7):823-31.
PMID: 23376846
PMC: 3929321.
DOI: 10.1038/onc.2013.3.
Identification of the cancer cell proliferation and survival functions of proHB-EGF by using an anti-HB-EGF antibody.
Sato S, Kamada H, Watanabe T, Tsuji I, Fan J
PLoS One. 2013; 8(1):e54509.
PMID: 23349913
PMC: 3549951.
DOI: 10.1371/journal.pone.0054509.
A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
Sato S, Drake A, Tsuji I, Fan J
PLoS One. 2012; 7(12):e51964.
PMID: 23251664
PMC: 3522611.
DOI: 10.1371/journal.pone.0051964.
Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer.
Kasai N, Kobayashi K, Shioya S, Yoshikawa Y, Yotsumoto F, Miyamoto S
Am J Transl Res. 2012; 4(4):415-21.
PMID: 23145209
PMC: 3493029.
Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods.
Tsuji I, Sato S, Otake K, Watanabe T, Kamada H, Kurokawa T
MAbs. 2012; 4(6):732-9.
PMID: 23007682
PMC: 3502240.
DOI: 10.4161/mabs.21929.
EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
Ardito C, Gruner B, Takeuchi K, Lubeseder-Martellato C, Teichmann N, Mazur P
Cancer Cell. 2012; 22(3):304-17.
PMID: 22975374
PMC: 3443395.
DOI: 10.1016/j.ccr.2012.07.024.
Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion.
Shimura T, Yoshida M, Fukuda S, Ebi M, Hirata Y, Mizoshita T
BMC Cancer. 2012; 12:205.
PMID: 22646534
PMC: 3414754.
DOI: 10.1186/1471-2407-12-205.
2-Triazenoazaindoles: α novel class of triazenes inducing transcriptional down-regulation of EGFR and HER-2 in human pancreatic cancer cells.
Kreutzer J, Salvador A, Diana P, Cirrincione G, Vedaldi D, Litchfield D
Int J Oncol. 2011; 40(4):914-22.
PMID: 22134789
PMC: 3584806.
DOI: 10.3892/ijo.2011.1272.
Epidermal growth factor receptor regulates pancreatic fibrosis.
Blaine S, Ray K, Branch K, Robinson P, Whitehead R, Means A
Am J Physiol Gastrointest Liver Physiol. 2009; 297(3):G434-41.
PMID: 19608732
PMC: 2739824.
DOI: 10.1152/ajpgi.00152.2009.
Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands.
Nakagawa M, Nabeshima K, Asano S, Hamasaki M, Uesugi N, Tani H
Cancer Sci. 2009; 100(4):654-62.
PMID: 19298600
PMC: 11158838.
DOI: 10.1111/j.1349-7006.2009.01089.x.
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.
Aikawa T, Whipple C, Lopez M, Gunn J, Young A, Lander A
J Clin Invest. 2007; 118(1):89-99.
PMID: 18064304
PMC: 2117766.
DOI: 10.1172/JCI32412.
Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells.
Hurtado M, Lozano J, Castellanos E, Lopez-Fernandez L, Harshman K, Martinez-A C
Gut. 2007; 56(9):1266-74.
PMID: 17452424
PMC: 1954978.
DOI: 10.1136/gut.2006.097188.
Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy.
Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E
Cancer Sci. 2006; 97(5):341-7.
PMID: 16630129
PMC: 11159358.
DOI: 10.1111/j.1349-7006.2006.00188.x.
Pathways for aberrant angiogenesis in pancreatic cancer.
Korc M
Mol Cancer. 2003; 2:8.
PMID: 12556241
PMC: 149422.
DOI: 10.1186/1476-4598-2-8.